Closing the gap in preventable blindness
Diabetic Retinopathy Disproportionately Affects the Underserved
The burden of diabetic retinopathy is not evenly distributed. Black, Hispanic, and low-income populations have higher rates of diabetes, lower rates of regular ophthalmology visits, and higher rates of vision loss from retinopathy. The reasons are structural: geographic distance from eye care specialists, lack of insurance coverage, and healthcare systems that were not designed with these populations in mind.
Why Traditional Screening Models Fall Short
A screening model that depends on patients self-initiating a referral to an ophthalmologist will always perform worst for the populations with the most barriers. Transportation, cost, work schedules, and distrust of specialty care all reduce follow-through — particularly in communities that already face systemic disadvantages in accessing healthcare.
Autonomous AI as an Equity Tool
By embedding retinal screening into existing primary care and community health center visits, autonomous AI removes the referral step that so many patients never complete. Screening happens where patients already are, without additional appointments, additional costs, or additional barriers.
Clinical data from EyeArt deployments at federally qualified health centers shows that screening uptake can exceed 90% of eligible patients when the technology is integrated into routine diabetes management visits — a figure that no referral-based model comes close to matching.
Consistent Performance Across Populations
A critical requirement for any equity-focused health technology is that it performs equally well across the populations it serves. Published subgroup analyses of EyeArt performance show no statistically significant differences in sensitivity or specificity across racial and ethnic groups — an essential finding for health systems deploying the technology in diverse patient populations.
The Path Forward
Autonomous AI screening is not a complete solution to health equity in diabetes care. But it is one of the most practical tools available today for expanding access to high-quality retinal screening for the patients who need it most.